Chardan Capital Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $30.00

4D Molecular Therapeutics (NASDAQ:FDMT) had its price target decreased by Chardan Capital from $39.00 to $30.00 in a report released on Tuesday,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Several other analysts have also recently weighed in on FDMT. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Saturday, February 1st. Bank of America reduced their price target on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. BMO Capital Markets lowered shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $40.00 to $15.00 in a report on Monday, January 13th. Finally, Leerink Partners dropped their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.13.

4D Molecular Therapeutics Stock Up 3.7 %

Shares of NASDAQ FDMT opened at $4.72 on Tuesday. The firm’s fifty day moving average is $5.65 and its 200 day moving average is $9.49. 4D Molecular Therapeutics has a 52 week low of $4.41 and a 52 week high of $36.25. The company has a market cap of $218.21 million, a price-to-earnings ratio of -1.66 and a beta of 2.81.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds have recently added to or reduced their stakes in FDMT. nVerses Capital LLC bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter worth approximately $40,000. Values First Advisors Inc. acquired a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at about $57,000. KLP Kapitalforvaltning AS acquired a new position in 4D Molecular Therapeutics during the fourth quarter worth $48,000. PNC Financial Services Group Inc. increased its position in shares of 4D Molecular Therapeutics by 66.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock worth $51,000 after purchasing an additional 3,630 shares in the last quarter. Finally, Daiwa Securities Group Inc. lifted its stake in 4D Molecular Therapeutics by 5,291.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock worth $55,000 after purchasing an additional 9,737 shares in the last quarter. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.